Copyright
©The Author(s) 2015.
World J Gastroenterol. Jan 7, 2015; 21(1): 254-261
Published online Jan 7, 2015. doi: 10.3748/wjg.v21.i1.254
Published online Jan 7, 2015. doi: 10.3748/wjg.v21.i1.254
Table 2 Demographic data and clinical features of responders
| Total (n = 15) | |
| Sex (patient number) | |
| Male | 9 |
| Female | 6 |
| Age at onset (yr; mean ± SE) | 26.2 ± 3.5 |
| Age at CyA treatment (yr; mean ± SE) | 30.5 ± 3.8 |
| Duration of UC (months; mean ± SE) | 62.3 ± 19.2 |
| Disease extent (patient number) | |
| Pancolitis | 12 |
| Left-sided colitis | 3 |
| Clinical course (patient number) | |
| Relapse-remitting | 11 |
| Chronic continuous | 3 |
| Acute fulminating | 1 |
| Initial attack | 0 |
- Citation: Miyake N, Ando T, Ishiguro K, Maeda O, Watanabe O, Hirayama Y, Maeda K, Morise K, Matsushita M, Furukawa K, Funasaka K, Nakamura M, Miyahara R, Ohmiya N, Goto H. Azathioprine is essential following cyclosporine for patients with steroid-refractory ulcerative colitis. World J Gastroenterol 2015; 21(1): 254-261
- URL: https://www.wjgnet.com/1007-9327/full/v21/i1/254.htm
- DOI: https://dx.doi.org/10.3748/wjg.v21.i1.254